HSPA7 and cancer: MMR deficiency has recently emerged as a beneficial indicator of the response to PD-1 blockade in patients with cancer (65, 66), whereas we found that HSPA7 was negatively correlated with MMR-related pathway activity (Figure 4A), which in turn was negatively correlated with stromal activation and oncogenic pathway activation (Figure 4B and Supplementary Figure S11).